Street Calls of the Week
Investing.com - Freedom Capital Markets initiated coverage on Golden Matrix Group, Inc. (NASDAQ:GMGI) with a Buy rating and a price target of $1.80, representing a potential upside of 80%. According to InvestingPro data, the company currently has a market capitalization of $138 million and shows a strong free cash flow yield, suggesting potential value opportunity.
The firm identified Golden Matrix as a B2B/B2C gaming company operating across multiple verticals including online casino, sports betting, prize competitions, and SaaS platforms. The company generates recurring revenue through its scalable gaming platforms and subscription-based models, achieving impressive revenue growth of 54.7% and maintaining a healthy gross profit margin of 56.6%.
Freedom Capital Markets highlighted GMGI’s global geographic and product expansion strategy as key factors in its positive outlook. The firm also noted the company’s integrated B2B/B2C ecosystem and proprietary technology platforms as competitive advantages.
These strengths position Golden Matrix to capture significant market share in newly regulated territories, according to the research note. The company’s business model focuses on recurring revenue streams through its gaming platforms.
The $1.80 price target reflects Freedom Capital Markets’ assessment of Golden Matrix’s growth potential in the gaming sector as it expands its presence across multiple markets and product categories.
In other recent news, Golden Matrix Group Inc. reported record revenue figures for August, achieving $17.8 million, which marks an 18% increase compared to the same month last year. The company also experienced strong financial performance in July, with revenue reaching $15.7 million, a 24% rise from July 2024. However, in its second-quarter 2025 earnings report, Golden Matrix revealed a net loss of $3.6 million, or $0.03 per share, which was below analysts’ expectations of a $0.0033 per share loss. Additionally, the company’s revenue for the quarter fell short of projections, coming in at $43.25 million against an anticipated $46.38 million. These recent developments highlight both positive revenue growth in specific months and challenges in meeting quarterly financial forecasts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.